Bristol Myers sues AstraZeneca over cancer-treatment patents
FILE PHOTO: A woman holds test tube in front of displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration
Bristol Myers Squibb Co, in a lawsuit made public on Friday, said AstraZeneca’s cancer treatment Imfinzi violates patents related to its blockbuster cancer drug Opdivo.
The lawsuit https://tmsnrt.rs/3ieYLvz in Delaware federal court said that the use of Imfinzi to treat lung and bladder cancer infringes several patents on Bristol’s immunotherapy Opdivo.
An AstraZeneca spokesperson said on Friday that the company was reviewing the complaint and would respond “at the appropriate time.”
A representative for Bristol Myers declined to comment.
New York-based Bristol Myers recorded over $7.5 billion from worldwide sales of Opdivo last year. Imfinzi brought in over $2.4 billion in sales for the British drugmaker last year.
Bristol asked the Delaware court for an undisclosed amount of monetary damages.
Opdivo (nivolumab) is a monoclonal antibody designed to block a protein that cancer cells use to avoid the immune system. The treatment essentially takes the brakes off the immune system to fight cancer.
Opdivo is approved for use against many types of cancer including melanoma and advanced lung, bladder, and kidney cancer.
Imfinzi (duralumab) works in a similar manner. The complaint, which cites several patents, says Bristol invented the methods for enhancing immune responses.
A Bristol Myers subsidiary previously won $1.2 billion from a Gilead Sciences unit whose lymphoma immunotherapy Yescarta from a different class of medicines was found to infringe one of its patents. A U.S. appeals court threw out that award last year.
RELATED STORY
Bristol Myers is sued for refusing COVID-19 vaccine religious exemptions
Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.
